Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
Volker Heinemann , Dominik Paul Modest , Ludwig Fischer von Weikersthal , Thomas Decker , Alexander Kiani , Ursula Vehling-Kaiser , Salah-Eddin Al-Batran , Tobias Heintges , Christian A. Lerchenmuller , Christoph Kahl , Gernot Seipelt , Frank Kullmann , Martina Stauch , Werner Scheithauer , Swantje Held , Clemens Albrecht Giessen , Andreas Jung , Thomas Kirchner , Sebastian Stintzing
Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. We analyzed the efficacy dependent on gender and primary tumor location within the RAS wild-type population (n=342). Methods: Primary tumor location was defined as follows: right sided CRC (RCRC): coecum to hepatic flexure; left sided CRC (LCRC): splenic flexure to rectum. Colon transversum tumors (n=9) were excluded. Differences in response (ORR) and survival (PFS/OS) within both treatment arms were calculated using two-sided Fisher´s exact and logrank test, respectively. Results: In location wise comparison LCRC shows better efficacy results (ORR, PFS and OS) when compared with RCRC especially in the cetuximab arm (Table). Female gender has a trend towards lower tumor response rates, shorter PFS and OS when compared to male patients. Conclusions: MCRC is a heterogeneous disease. Treatment efficacy depends on primary tumor location and patients’ gender. Effects were more prominent in patients receiving FOLFIRI plus cetuximab where male patients with LCRC tumors are favored.
FOLFIRI + Cetuximab n=167 |
FOLFIRI + Bevacizumab n=166 |
|||||
---|---|---|---|---|---|---|
RCRC n=30 |
LCRC n=137 |
p | RCRC n=39 |
LCRC n=127 |
p | |
ORR (%) | 46.7 | 70.1 | 0.019# OR: 2.7 |
48.7 | 62.2 | 0.14# OR: 1.7 |
PFS (mo) | 6.9 | 10.8 | <0.0001* HR: 0.35 |
8.8 | 10.5 | 0.065* HR: 0.69 |
OS (mo) | 16.1 | 38.7 | <0.0001* HR: 0.26 |
22.7 | 28.0 | 0.034* HR: 0.63 |
female n=44 |
male n=123 | p | male n=54 |
male n=112 | p | |
ORR (%) | 54.5 | 69.9 | 0.095# OR: 1.9 |
55.6 | 60.7 | 0.61# OR: 1.24 |
PFS (mo) | 9.2 | 10.6 | 0.005* HR: 0.60 |
9.1 | 10.3 | 0.051* HR: 0.70 |
OS (mo) | 27.9 | 36.4 | 0.12* HR: 0.71 |
25.9 | 24.8 | 0.8* HR: 1.05 |
Abbreviations: Bev, bevacizumab; Cet, cetuximab; OR, Odds ratio; HR, hazard ratio; mo, months. *= logrank p; #= two-sided Fisher’s exact p.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Sebastian Stintzing
2023 ASCO Annual Meeting
First Author: Sebastian Stintzing
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Zev A. Wainberg
2023 ASCO Annual Meeting
First Author: Anna Maria Rachiglio